Latest Research
Chasing the target: reports from the Advances in Targeted Therapies meeting, 2025. Annals of the Rheumatic Diseases, April 2026
autoscoRA: Deep Learning to Automate Sharp/van der Heijde Scoring of Radiographic Damage in Rheumatoid Arthritis. Arthritis Rheumatol., April 2026
Efficacy of synthetic and biological DMARDs: a systematic literature review informing the 2025 update of the EULAR recommendations for the management of rheumatoid arthritis. Annals of the Rheumatic Diseases, April 2026
Safety of synthetic and biological DMARDs: a systematic literature review informing the 2025 update of the EULAR recommendations for the management of rheumatoid arthritis. Annals of the Rheumatic Diseases, April 2026
The synovial interface: At the intersection from cells to humans. Annals of Anatomy, April 2026
EULAR recommendations for the management of rheumatoid arthritis with synthetic and biologic disease-modifying antirheumatic drugs: 2025 update. Annals of the Rheumatic Diseases, March 2026. Media coverage:1, 2, 3, 4, 5, 6
International IVIg prescription patterns in idiopathic inflammatory myopathies: real-world insights from the MyoNet survey. EULAR Rheumatology Open, March 2026
Do high rheumatoid factor levels impact response to certolizumab pegol in patients with inadequately controlled rheumatoid arthritis? A post hoc analysis of the phase IIIb REALISTIC trial. RMD Open, January 2026
Research Group of Helga Lechner-Radner
Outcome Research in RheumatologyWe stand at the forefront of bridging clinical trials, digital health, and patient-centered outcome research, making every step in rheumatology care more evidence-based, precise, and meaningful for patients.
Research Group of Peter Mandl
Rheumatology Imaging Group Vienna (RIG Vienna)We perform and interpret imaging studies encompassing all manifestations of rheumatic and musculoskeletal diseases and develop new diagnostic and therapeutic methods targeting fibroblasts.
Research Group of Daniela Sieghart
Biomarkers in rheumatic disordersWe study autoantibodies as potential biomarkers for diagnosis, management and prognosis of rheumatic conditions.
Research Group of Paul Studenic
We try to understand the validity of outcomes used in measuring disease activity, progression, quality of life and the interaction of patients with the health care system.
Research Group Autoimmunity and Immunodeficiency
We study, treat and manage patients with immune mediated inflammatory diseases as well as patients with primary or secondary immunodeficiencies.
Research Group RHEPRO
RHEumatic disease and RePROductionWe conduct translational research on the impact of rheumatic diseases on fertility, pregnancy, and the development of the fetal and neonatal immune system, and develop interdisciplinary strategies to improve diagnostics, therapy, and patient care.